Catalyst Biosciences Stock Cut in Half on Halted Drug Trial

CBIO stock is headed for its worst day since late 2011

Jun 18, 2018 at 10:39 AM
facebook twitter linkedin


Shares of Catalyst Biosciences Inc (NASDAQ:CBIO) are spiraling today, after the drugmaker provided an update on an early stage trial for its hemophilia B treatment. Specifically, the study has been put on hold until it can be determined why the two patients enrolled developed neutralizing antibodies after being treated with the next-generation Factor IX (FIX) candidate CB 2679d/ISU304.

Pouring salt on the proverbial wound, Ladenburg Thalmann nearly halved its CBIO price target to $24.50 from $47.00. Against this backdrop, Catalyst Biosciences stock was last seen down 54.2% to trade at $11.56 -- on track for its worst day since Nov. 8, 2011 -- slicing through recent support at its 120-day moving average, and falling into negative year-to-date territory for the first time since early January.

cbio stock daily chart june 18

The volatile price action has sparked a rush of activity in CBIO's typically quiet options pits. Most recently, about 1,200 puts and 867 calls were on the tape -- 21 times what's typically seen, and volume pacing in the 100th annual percentile. Shorter-term traders are targeting July and August 17.50 calls, where it looks like new positions are possibly being purchased.

While this would imply options traders are betting on a quick bounce for the shares, there's plenty of room for analysts to downwardly revise their ratings -- which could keep the pressure on CBIO stock in the near term. Currently, all three covering brokerage firms maintain a "strong buy" rating, while the average 12-month price target stands all the way up at $48.44.

 

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners